Pulmonx Q1 revenue falls, slightly beats estimates

Pulmonx

29/04/2026 21:22

Overview

Minimally invasive lung device maker's Q1 revenue fell 9% yr/yr, slightly beating analyst expectations

Company's international revenue dropped 12%

Gross margin improved to 78% from 73% a year ago

Outlook

Pulmonx continues to expect 2026 revenue between $90 mln and $92 mln

Company maintains 2026 gross margin outlook at approximately 75%

Pulmonx expects 2026 operating expenses of $113 mln to $115 mln, including $19 mln stock-based compensation

Result Drivers

CHINA REGISTRATION DELAY - Co said international revenue decline was due to lack of China sales as it awaits renewal of its registration certificate

U.S. SALES STRATEGY - Co cited initiation of refreshed U.S. commercial strategies and refocused sales organization as factors influencing Q1 performance

Company press release: ID:nGNX6ZFqCm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Beat*
$20.59 mln
$20.43 mln (5 Analysts)
Q1 EPS
-$0.33
Q1 Net Income
-$13.65 mln
Q1 Gross Profit
$16.04 mln
Q1 Pretax Profit
-$13.51 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Pulmonx Corp is $3.50, about 184.6% above its April 28 closing price of $1.23

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)